WGS GeneDx Holdings Corp.

NEUTRAL Impact: 3/10 8-K
Horizon weeks Filed Jun 16, 2026 Processed 2d 23h ago SEC 0001628280-26-043431
8-K context-dependent: Items 5.02, 7.01
Latest settled — T+1d
WGS ▼ -6.90% at T+1d
NEUTRAL call ✗ call lost -6.90% · α vs SPY -5.65% · entry $60.60 → $56.42
Next anchor: T+5d in 5d
Last close $56.42 (close Jun 17) · -6.90% from $60.60 entry
Entry anchored
Jun 15, 03:59 PM ET
via Databento tick
T+1d
-6.90%
call -6.90% · α -5.65%
$56.42
settled yesterday
T+5d
call — · α —
in 5d
T+20d
call — · α —
in 26d
T+60d
call — · α —
in 3mo

Price Chart

Loading chart...

Executive Summary

GeneDx appointed Mark Gardner as President, effective June 15, 2026, to oversee lab and commercial operations. Gardner, a former Quest Diagnostics executive, received a compensation package including a $530,000 base salary, 65% target bonus, and $2,000,000 in restricted stock units. This is a routine executive hire with no financial data or guidance provided.

Actionable Insight

This is a routine executive appointment with no immediate financial impact. Monitor upcoming quarterly results for any operational execution changes under the new President. The hire signals focus on scaling commercial operations, but no guidance or financial data was provided.

Key Facts

  • Mark Gardner appointed President effective June 15, 2026, reporting to CEO Katherine Stueland
  • Gardner previously served as SVP of Molecular Genomics and Oncology at Quest Diagnostics (Sept 2022 – June 2026)
  • Employment agreement: $530,000 annual base salary, 65% target bonus, $2,000,000 in RSUs vesting over 4 years
  • Bryan Dechairo transitions to lead product, technology and innovation initiatives
  • No financial results, guidance, or material operational metrics disclosed in the filing

Financial Impact

Compensation package for new President: $530,000 base salary, $344,500 target bonus, $2,000,000 in RSUs

executive compensation

Risk Factors

  • No financial data or guidance provided to assess impact on operations
  • Historical performance on WGS reports shows negative average T+20 returns (-4.79%) and low win rate (25%), suggesting limited market reaction to similar filings

Market Snapshot

Exchange
Nasdaq
Sector
Services-Health Services
Analyst Consensus
92% bullish (13 analysts)

Documents Analyzed

This report is based on 5 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001628280-26-043431
Exhibit: exhibit991-6162026pressrel.htm0001628280-26-043431
Document: 0001628280-26-043431-index-headers.html0001628280-26-043431
Document: 0001628280-26-043431-index.html0001628280-26-043431
Document: 0001628280-26-043431.txt0001628280-26-043431
7 reports for WGS
Performance horizon
100% Hit rate 5 of 5 directional calls best @ T+60▲ +36.89%Mar 4, 2026
Filters
Rows
Reports for WGS — sortable, filterable
Type Now
Jun 16, 2026
2d ago
8-K
NEUTRAL ★ 3/10
$60.60 $56.42▼ −6.90%▼ −5.65%$56.42 (−6.90%)
Jun 11, 2026
7d ago
Institutional Cluster
BULLISH ★ 4/10
$59.92 $61.32▲ +2.34%▲ +0.57%$56.42 (−5.84%)
Jun 8, 2026
10d ago
Insider Cluster
BULLISH ★ 6/10
$56.33 $54.32▼ −3.57%▼ −1.99%$56.42 (+0.16%)
May 20, 2026
29d ago
Insider Cluster
BULLISH ★ 6/10
$47.33 $47.31▼ −0.04%▼ −0.49%$56.42 (+19.21%)
Mar 26, 2026
12w ago
Insider Cluster
BEARISH ★ 6/10
$61.35 $57.09▲ +6.94%▲ +5.26%$56.42 (+8.04%)
Mar 4, 2026
15w ago
Insider Cluster
BEARISH ★ 6/10
$79.47 $82.00▼ −3.18%▼ −3.76%$56.42 (+29.00%)
Mar 4, 2026
15w ago
Insider Cluster
NEUTRAL ★ 4/10
$79.47 $82.00▲ +3.18%▲ +3.76%$56.42 (−29.00%)
Showing 7 of 7

US Market Status

Market Closed — Juneteenth — Opens Mon (73h 32m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access